Results 151 to 160 of about 276,101 (206)
An injectable bimodal TCPD nanodepot disrupts glutaminolysis and TCA metabolism, sensitizing large tumors to spatially complementary sono‐thermal ablation for complete treatment coverage. This intervention induces mitochondrial and endoplasmic reticulum dysfunction, genotoxicity, and NAD+ depletion, converging to trigger PANoptosome assembly and ...
Yi‐Ming Liu +10 more
wiley +1 more source
Nutritional Management in Patients With Hematological Malignancies: An Underestimated Supportive Care Issue. [PDF]
El Ouafa Y +3 more
europepmc +1 more source
An engineered peptide self‐assembled nanofiber platform, designed to replicate STING–cGAMP binding motifs, facilitates pH‐responsive cytosolic delivery of cGAMP, enhances the endoplasmic reticulum with high efficiency, and robustly activates the STING pathway.
Yubin He +6 more
wiley +1 more source
Antibody-Drug Conjugates in Hematological Malignancies: Current Landscape and Future Perspectives. [PDF]
Montalbano MC +3 more
europepmc +1 more source
This work reports conceptually unprecedented topological quantum biomaterials derived from engineered Pd3Sn nanostrips for oncological applications. Their near‐Fermi‐level electronic architecture and superior interfacial charge transport facilitate ultrasound‐amplified redox reactions and efficient ROS generation.
Zilu Chen +10 more
wiley +1 more source
A Clinical Investigation of Hypoxic Red Blood Cell Administration in Patients with Transfusion-Dependent Hematological Malignancies and Burns. [PDF]
Reikvam H +5 more
europepmc +1 more source
This study reveals that large tumors secrete more chemokine CXCL3, which recruits immunosuppressive neutrophils to the periphery, thereby impairing the activation and memory of systemic tumor‑reactive CD8+ T cells. CXCL3 antagonism restores systemic immune memory and enhances the antitumor efficacy of anti‑PD‑1 therapy, offering a potential strategy to
Ji Wang +15 more
wiley +1 more source
Population pharmacokinetic analysis of pirtobrutinib, a non-covalent BTK inhibitor, in patients with hematological malignancies from the Phase 1/2 BRUIN study. [PDF]
Bell R +4 more
europepmc +1 more source
A dual‐transmembrane Bicephali CAR‐T platform simultaneously targets CD276 and NKG2D ligands to address antigen heterogeneity in non‐small cell lung cancer. By improving immune synapse formation, mitochondrial fitness, antioxidant capacity, and stem‐like persistence, this design enhances durable tumor control and provides a versatile strategy to ...
Lina Wang +8 more
wiley +1 more source

